145 related articles for article (PubMed ID: 17401099)
41. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.
Jansen NL; Suchorska B; Wenter V; Eigenbrod S; Schmid-Tannwald C; Zwergal A; Niyazi M; Drexler M; Bartenstein P; Schnell O; Tonn JC; Thon N; Kreth FW; la Fougère C
J Nucl Med; 2014 Feb; 55(2):198-203. PubMed ID: 24379223
[TBL] [Abstract][Full Text] [Related]
42. O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results.
Stegmayr C; Willuweit A; Lohmann P; Langen KJ
Curr Radiopharm; 2019; 12(3):201-210. PubMed ID: 30636621
[TBL] [Abstract][Full Text] [Related]
43. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
44. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas.
Langen KJ; Jarosch M; Mühlensiepen H; Hamacher K; Bröer S; Jansen P; Zilles K; Coenen HH
Nucl Med Biol; 2003 Jul; 30(5):501-8. PubMed ID: 12831987
[TBL] [Abstract][Full Text] [Related]
45. O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes.
Rau FC; Weber WA; Wester HJ; Herz M; Becker I; Krüger A; Schwaiger M; Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1039-46. PubMed ID: 12173018
[TBL] [Abstract][Full Text] [Related]
46. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.
Pirotte B; Goldman S; Massager N; David P; Wikler D; Vandesteene A; Salmon I; Brotchi J; Levivier M
J Nucl Med; 2004 Aug; 45(8):1293-8. PubMed ID: 15299051
[TBL] [Abstract][Full Text] [Related]
47. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine and L-3H-methionine uptake in cerebral hematomas.
Salber D; Stoffels G; Oros-Peusquens AM; Shah NJ; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
J Nucl Med; 2010 May; 51(5):790-7. PubMed ID: 20395334
[TBL] [Abstract][Full Text] [Related]
48. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
[TBL] [Abstract][Full Text] [Related]
49. Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats.
Lee TS; Ahn SH; Moon BS; Chun KS; Kang JH; Cheon GJ; Choi CW; Lim SM
Nucl Med Biol; 2009 Aug; 36(6):681-6. PubMed ID: 19647174
[TBL] [Abstract][Full Text] [Related]
50. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
[TBL] [Abstract][Full Text] [Related]
51. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.
Henriksen OM; Larsen VA; Muhic A; Hansen AE; Larsson HBW; Poulsen HS; Law I
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):103-112. PubMed ID: 26363903
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.
Floeth FW; Pauleit D; Sabel M; Stoffels G; Reifenberger G; Riemenschneider MJ; Jansen P; Coenen HH; Steiger HJ; Langen KJ
J Nucl Med; 2007 Apr; 48(4):519-27. PubMed ID: 17401087
[TBL] [Abstract][Full Text] [Related]
53. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
54. Combination of MRI and dynamic FET PET for initial glioma grading.
Dunet V; Maeder P; Nicod-Lalonde M; Lhermitte B; Pollo C; Bloch J; Stupp R; Meuli R; Prior JO
Nuklearmedizin; 2014 Aug; 53(4):155-61. PubMed ID: 24737132
[TBL] [Abstract][Full Text] [Related]
55. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
56. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.
Pöpperl G; Kreth FW; Mehrkens JH; Herms J; Seelos K; Koch W; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1933-42. PubMed ID: 17763848
[TBL] [Abstract][Full Text] [Related]
57. Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas.
Stegmayr C; Schöneck M; Oliveira D; Willuweit A; Filss C; Galldiks N; Shah NJ; Coenen HH; Langen KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1115-23. PubMed ID: 26646781
[TBL] [Abstract][Full Text] [Related]
58. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy.
Calcagni ML; Galli G; Giordano A; Taralli S; Anile C; Niesen A; Baum RP
Clin Nucl Med; 2011 Oct; 36(10):841-7. PubMed ID: 21892031
[TBL] [Abstract][Full Text] [Related]
59. (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection.
Kaim AH; Weber B; Kurrer MO; Westera G; Schweitzer A; Gottschalk J; von Schulthess GK; Buck A
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):648-54. PubMed ID: 11976803
[TBL] [Abstract][Full Text] [Related]
60. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis.
Dunet V; Rossier C; Buck A; Stupp R; Prior JO
J Nucl Med; 2012 Feb; 53(2):207-14. PubMed ID: 22302961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
